APC-Targeted Antibody IL-10 Conjugates for Autoimmune Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune and inflammatory disorders often rely on non-specific immunosuppression, which can lead to severe infections and lethal consequences, highlighting a need for therapies that can target and suppress autoimmune responses without global immunosuppression.

Innovation Solution

Development of APC-targeted antibodies operatively linked to IL-10 or its fragments, which are specifically delivered to antigen-presenting cells to inhibit inflammatory or autoimmune responses, thereby inducing immune tolerance and reducing pathogenic T cell responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-specific immunosuppressants are used to treat autoimmune diseases, then immune response is suppressed, but severe infections and lethal consequences occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidsevere infections

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by directing the anti-inflammatory cytokine IL-10 specifically to antigen-presenting cells (APCs) through APC-targeted antibodies, rather than providing non-specific immunosuppression. This localized delivery ensures that immune suppression occurs only at the site of autoimmune pathology (APCs), while leaving other immune functions intact and preserving the host's ability to fight infections.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses APC-targeted antibodies as intermediaries to deliver IL-10 to antigen-presenting cells. These antibodies serve as mediators that bridge the gap between the administered cytokine and its target cells, enabling specific and controlled immune modulation without the harmful effects of non-specific immunosuppression.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If APC-targeted antibodies linked to IL-10 are used, then immune tolerance is induced with lower dose, but device complexity increases

Engineering Contradiction:

ImproveIL-10 dose requirementVSAvoidantibody conjugate structure

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent merges two functional components into a single conjugate molecule: the APC-targeted antibody and the anti-inflammatory cytokine IL-10. This combining approach allows the antibody to serve dual purposes - both targeting APCs and delivering the therapeutic cytokine, thereby reducing the total dose of IL-10 needed while achieving the desired immune tolerance effect.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The APC-targeted antibody acts as an intermediary carrier that facilitates the delivery of IL-10 to its target cells. This intermediary approach increases the efficiency of cytokine delivery, allowing lower doses of IL-10 to achieve the same therapeutic effect that would otherwise require higher doses administered without targeting.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS11957734B2Methods and compositions for treating autoimmune and inflammatory conditions

Publication Date: 2024.04.16 BAYLOR RESEARCH INSTITUTE

AI summary

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.